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Autoimmune hemolytic anemia (AIHA) is a very rare cause of anemia in a case of malaria.\[[@ref1]\] AIHA represents a group of disorders in which the presence of autoantibodies directed against self-antigens, leads to shortened red cell survival.\[[@ref2]\] Anemia occurs in malaria due to invasion and destruction of red blood cells (RBCs) by malarial parasite, splenic sequestration, and ineffective erythropoiesis. Parenteral artesunate is recommended as the first-line therapy for severe and complicated malaria.\[[@ref3]\] While superiority in terms of survival has been proven when IV artesunate was compared to quinine in controlled trials in Asia (South East Asian Quinine Artesunate Malaria Trial \[AQUAMAT\])\[[@ref4]\] and Africa (AQUAMAT),\[[@ref5]\] little evidence is available regarding long-term side effects. There are few reports pointing out the occurrence of late onset hemolysis secondary to artesunate administration.\[[@ref6][@ref7][@ref8][@ref9][@ref10]\] However, AIHA should be considered a relatively rare cause of anemia in malaria.

We describe a very rare case of AIHA following treatment of severe malaria managed with parenteral artesunate with clinical and hemato-biochemical features indicating drug-related mechanism.

C[ASE]{.smallcaps} R[EPORT]{.smallcaps} {#sec1-2}
=======================================

A 50-year-old patient presented with a history of fever associated with chills, generalized body aches and headache of 8 days duration. There was a history of yellowish discoloration of urine of 8--10 days duration. At the time of presentation, the patient was drowsy with toxic looks and features of sepsis. Clinically, he had tachycardia, tachypnea, hypotension (blood pressure-80/50), icterus, and minimal pedal edema. Systemic examination revealed mild hepatosplenomegaly with crepitation over the right infra-scapular region. Peripheral blood smear showed trophozoites of Plasmodium vivax and ring forms of plasmodium falciparum with a parasite index of 45% \[[Figure 1](#F1){ref-type="fig"}\]. Arterial blood gas showed metabolic acidosis and hyperlactemia. Ultrasonography abdomen revealed hepatosplenomegaly with mild ascites. Chest X-ray posteroanterior view showed mild right-sided pleural effusion. Hemoglobin (Hb) level was 12.5% with a platelet count of 45,000 \[[Figure 2](#F2){ref-type="fig"}\]. There were deranged renal parameters (serum urea-134 mg, serum creatinine-4.6 mg) with abnormal liver function test. (Serum bilirubin-4.6 mg, aspartate aminotransferase-96 IU, alanine aminotransferase-136 IU) \[[Figure 3](#F3){ref-type="fig"}\]. Based on clinical and laboratory parameters, the patient was diagnosed as a case of complicated malaria (mixed infection-BT+MT) and started on anti-malarials (injection artesunate), broad-spectrum antibiotics, inotropes, and supportive care. Patients condition showed steady improvement with fever settling down, and he was hemodynamically stable with lactate level returning to normal and parasitic index reduced from 45% to \<1% by the 7^th^ day of treatment \[[Figure 4](#F4){ref-type="fig"}\]. On the 8^th^ day of treatment, the patient had cola colored urine \[[Figure 5](#F5){ref-type="fig"}\] with Hb dropped to 8 g% and lactate dehydrogenase (LDH) of 1855 \[[Figure 6](#F6){ref-type="fig"}\]. Peripheral blood smear showed normocytic normochromic anaemia with features of hemolysis. Direct Coomb test was positive for immunoglobulin G (IgG) and blood sample sent for crossmatch was not compatible. On the 11^th^ day of admission, his Hb had rapidly fallen to 4.1 g % \[[Figure 2](#F2){ref-type="fig"}\] and LDH was 2436 IU \[[Figure 6](#F6){ref-type="fig"}\]. Patient had decreased haptoglobin with reticulocytosis (3.5%) and increase in unconjugated bilirubin. Other tests to find the cause of AIHA were done. Hemoglobinopathies, enzymopathies has been ruled out. Screening for hepatotropic viruses (hepatitis B and C viruses, HIV), dengue serology, cytomegalovirus, Epstein-Barr virus, parvo B-19 viruses, and antinuclear antibody was negative. The patient was given saline washed O negative blood which showed the least incompatibility on crossmatch with uneventful post-transfusion period. His Hb remained lower (4.8--6.5 g%) over the next 10 days. Given above clinical, biochemical and hematological findings, patient was diagnosed with a case of autoimmune hemolytic anemia and was started on corticosteroids (tablet methyl-prednisolone 60 mg per day) which were progressively tapered over next 2 months. Hb level gradually increased and over 2 months follow-up became 12 g%. At that time, LDH and haptoglobin were within normal limits, and direct coombs test (DCT) was negative, both for IgG and C3d.
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D[ISCUSSION]{.smallcaps} {#sec1-3}
========================

Anemia is very often encountered in malaria and the most common cause is hemolysis or splenic sequestration of RBCs.\[[@ref11]\] In our case, the patient had a high parasite index (45%) at presentation with Hb of 11 g%. He was managed with I/V artesunate and other supportive measures. The Hb started dropping to 8.3 g% by the 7^th^ day of treatment, and Peripheral Blood Smear (PBS) showed significant clearance of the parasites (\<1%) \[[Figure 4](#F4){ref-type="fig"}\]. This fall of Hb can be explained by lysis of the parasitized erythrocytes; however, the Hb fell further to 4.5 g% by the 11^th^ day \[[Figure 2](#F2){ref-type="fig"}\]. This late fall of Hb was perplexing. Hemolysis was evident by reticulocyte count above 3%, raising LDH level \[[Figure 6](#F6){ref-type="fig"}\], reduced haptoglobin levels and increased unconjugated bilirubin. The test for hemoglobinopathies (Thalassemia and sickle cell disease), membranopathies (hereditary spherocytosis), and enzymopathies such as glucose-6-phosphate dehydrogenase deficiency was normal. On further evaluation, DCT was positive, which showed that anemia might be because of autoimmune reasons, likely to be artesunate induced, as other possible causes were ruled out. Raffray *et al*.,\[[@ref12]\] in a case report reported severe delayed autoimmune hemolytic anemia following artesunate administration in severe malaria. In our case, also the autoimmune cause of hemolytic anemia is being thought and the probable reason may be artesunate injections given to the patient. The patient recovered and Hb level rose to 12 g% over 6 weeks.

The patient was not anemic on admission and was having normal splenic size. He was started on Injectable artesunate given high parasite index. Although the peripheral blood smear showed clearing of malarial parasites, the Hb level started to drop, and it became 4.9 g% over 11 days course. If it is a certainty that malaria was responsible for hemolytic anemia during the 1^st^ week, the negative finding for malarial parasites in blood smear ruled out its implication in the re-appearance of hemolysis, likely to be artesunate induced. There have been two case reports of association of malaria and autoimmune hemolysis from Korea and Canada.\[[@ref13][@ref14]\] Immune-mediated hemolysis may be another mechanism responsible for artesunate related delayed hemolytic anemia. The outcome was slowly favorable while using glucocorticoids.

C[ONCLUSION]{.smallcaps} {#sec1-4}
========================

This is a rare case of AIHA following treatment of severe malaria managed with parenteral artesunate with strong co-relation for the drug immune-related mechanism. Further research is warranted to characterize the cause of post-treatment hemolysis following parenteral artesunate administration in severe malaria patients.
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